← All trials
NCT01255371
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- May 1, 2013
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- French National Agency for Research on AIDS and Viral HepatitisLead sponsor
- University of LimpopoOverall official - principal investigator
- Government of FranceOverall official - principal investigator
- Mbeya Referral Hospital, TanzaniaOverall official - principal investigator
- University of LimpopoCollaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- Swiss National Science FoundationCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Government of FranceCollaborator
- Mbeya Referral Hospital, TanzaniaCollaborator
- Ludwig Maximilians UniversityCollaborator
- University of GenevaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.